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Abbreviations: AFM, atomic force microscopy; CAV1, caveolin-1; COL, collagen; 
ECL, enhanced chemiluminescence; ECM, extracellular matrix; FN, fibronectin; 
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analysis; KFs, keloid fibroblasts; MLC, myosin light chain; NFs, normal fibroblasts; 
PA, polyacrylamide; PDMS, polydimethylsiloxane; siNC, non-targeting control 
siRNA; siRNA, short interfering RNA; TCP, tissue culture plastic; TSA, trichostatin 
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ABSTRACT 
Keloids are pathological scars characterized by excessive extracellular matrix 
production that are prone to form in body sites with increased skin tension. 
Caveolin-1 (CAV1), the principal coat protein of caveolae, has been associated with 
the regulation of cell mechanics, including cell softening and loss of stiffness 
sensing ability in NIH3T3 fibroblasts. Although CAV1 is present in low amounts in 
keloid fibroblasts (KFs), the causal association between CAV1 downregulation and 
its aberrant responses to mechanical stimuli remain unclear. In this study, atomic 
force microscopy showed that KFs were softer than normal fibroblasts with a loss of 
stiffness sensing. The decrease of CAV1 contributed to the hyperactivation of 
fibrogenesis-associated RUNX2, a transcription factor germane to 
osteogenesis/chondrogenesis, and increased migratory ability in KFs. Treatment of 
KFs with trichostatin A (TSA), which increased the acetylation level of histone H3, 
increased CAV1 and decreased RUNX2 and fibronectin. TSA treatment also resulted 
in cell stiffening and decreased migratory ability in KFs. Collectively, these results 
suggest a novel role for CAV1 downregulation in linking the aberrant 
responsiveness to mechanical stimulation and extracellular matrix accumulation 
with the progression of keloids, findings that may lead to new developments in the 
prevention and treatment of keloid scarring. 
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INTRODUCTION 
 Keloids occur as a result of abnormal wound healing, and are characterized by 
excessive deposition of collagen in the dermis with extension of scar tissue beyond 
the original borders of wounds (Bran et al., 2009; Niessen et al., 1999). 
Pathologically, keloids are characterized by thick hyalinized eosinophilic collagen 
fibers (keloidal collagen) and a horizontal, tongue-like advancing edge in the upper 
dermis (Jumper et al., 2015; Lee et al., 2004). The etiology and molecular 
mechanism of keloid formation have not been fully elucidated, and effective 
prevention or treatment for keloids is still lacking (Tziotzios et al., 2012). 
     Human skin is a highly specialized mechanoresponsive organ, which 
continually senses and adapts to various mechanical stimuli (Ogawa and Hsu, 2013; 
Wong et al., 2011). Keloids tend to form in areas of the body subjected to increased 
skin tension or stiffness, such as the presternum and shoulders (Ogawa et al., 2011). 
A simulated finite element analysis showed that mechanical stimulation (i.e. 
skin-stretching tension) strongly influences the cellular behavior that leads to keloid 
growth (Akaishi et al., 2008). Thus, decreasing skin tension has been suggested as 
potentially beneficial for treating keloids (Ogawa et al., 2011).  
  As observed for chemical stimuli, matrix stiffness also has a large impact on the 
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regulation of cell behavior, such as survival, proliferation, differentiation, and 
migration (Stroka and Konstantopoulos, 2014; Wang et al., 2007). Moreover, several 
proteins, such as FAK and integrins, are found to play key roles in the 
mechanosensing and mechanotransduction of cells (Jansen et al., 2015). Recently, we 
found that decreased Caveolin-1 (CAV1) contributes to cell softening and loss of 
rigidity sensing ability in Ha-RasV12-transformed fibroblasts (Lin et al., 2015). CAV1, 
a major component of caveolae, plays an important role in signal transduction, 
membrane traffic and cholesterol transport (Boscher and Nabi, 2012). In addition to 
its primary role as a tumor suppressor, CAV1 has been linked to the regulation of 
focal adhesions and integrin-mediated actin remodeling, which have been widely 
studied for their role in mechanotransduction (Nethe and Hordijk, 2011; Radel et al., 
2007; Yang et al., 2011a). In various fibrotic disorders, including idiopathic 
pulmonary fibrosis, systemic sclerosis, and keloids, Cav1 was downregulated (Del 
Galdo et al., 2008; Wang et al., 2006; Zhang et al., 2011). Collectively, we speculate 
that, in keloid fibroblasts (KFs), a decrease in CAV1 may result in an aberrant 
response to the mechanical stimuli from the local environment. 
    Epigenetic mechanisms are important in regulating the wound healing 
processes, including keratinocyte proliferation, differentiation, and migration, 
together with dermal regeneration and neoangiogenesis (Lewis et al., 2014). The 
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histone deacetylase (HDAC) inhibitor, trichostatin A (TSA), has potent 
antifibrogenic effects in a mouse model of bleomycin-induced skin fibrosis (Huber 
et al., 2007). Treatment of fibroblasts with TSA causes abrogated TGF-β1-induced 
collagen gene expression (Ghosh et al., 2007; Rombouts et al., 2002). Russell et al. 
(2010) found epigenetic modifications in KFs that include an altered pattern of DNA 
methylation and histone acetylation. Although HDAC inhibition by TSA has been 
shown to inhibit collagen synthesis of KFs (Diao et al., 2011), the molecular 
mechanism underpinning this response remains unknown. 
 Our study aims to understand the mechanical properties of KFs and the 
mechanisms underlying the hyperresponsiveness of KFs to mechanical stimuli. 
RESULTS 
Keloid tissues are stiffer than normal dermal tissues, whereas keloid fibroblasts 
(KFs) are softer than normal dermal fibroblasts 
 Comparison of ECM levels in dermal tissues from keloid lesions and normal 
dermis revealed a relative increase in fibronectin (FN), and collagen (COL)1A1, 
COL3A1, and COL11A1 in the keloid tissues (Figure 1a and b). Atomic force 
microscopy (AFM) indentation measurements showed that keloid tissues (14213 ± 
1047 Pa) were approximately 10-fold stiffer than normal skin tissue (2406 ± 1035 
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Pa) (p<0.01) (Figure 1c and Supplementary Figure S1). This ECM accumulation in 
keloid lesions could be due to a corresponding increase in the amounts of ECM 
produced by the KFs (Figure 1d and e). However, at the cellular level, KFs (1133 ± 
77 Pa) were softer than normal fibroblasts (NFs) (1539 ± 113 Pa) from healthy 
subjects (p<0.01) (Figure 1f and g). 
RUNX2 is a potential key regulator for ECM overproduction in keloids 
 We analyzed the microarray results from 7 Japanese patients with keloids. A 
total of 345 upregulated genes (>4-fold), 86 downregulated genes (<-4-fold) and 15 
transcription regulators were identified in the keloid tissue compared with adjacent 
normal tissue (discarded skin as “dog ear” for aesthetic reason). Using Ingenuity 
Pathway Analysis (IPA) software (http://www.ingenuity.com), canonical pathway 
analysis revealed that the pathway of “the role of osteoblasts, osteoclasts, and 
chondrocytes in rheumatoid arthritis” was the most important signaling pathway, 
highlighting 17 significantly upregulated and one downregulated gene from the 
comparative dataset (Supplementary Figure S2). The upstream regulatory analysis 
revealed three key transcription regulators in the keloid group, including runt-related 
transcription factor 2 (RUNX2), NK3 homeobox 2 (NKX3-2), and MLX-interacting 
protein-like (MLXIPL) (Supplementary Table S1). Among these, RUNX2 plays a 
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vital role in regulating the downstream ECM proteins, including COL11A1, which 
is predominantly found in cartilage (Figure 2a). The expression of RUNX2 in 
dermal tissues was examined by immunohistochemistry on various tissue sections of 
normal skin, normal scar, hypertrophic scar and keloid tissue (Figure 2b). Among 
these tissues, the highest percentage of fibroblasts with nuclear RUNX2, was found 
in keloid tissue (Figure 2c). Immunoblotting of lysates from normal and keloid 
tissues showed that pRUNX2 (the active form of RUNX2) and RUNX2 were 
upregulated, albeit showing no statistical significance, in keloid tissue (Figure 2d 
and e). However, NFs expressed similar levels of pRUNX2 and RUNX2 as 
compared to KFs after culture on tissue culture plastic (TCP) dish (Figure 2f and g). 
The role of RUNX2 in the overproduction of ECMs in KFs was validated using 
short interfering RNA (siRNA) to silence RUNX2. Suppression of RUNX2 
downregulated the mRNA level of FN and COL11A1 in KFs (Supplementary Figure 
S3). Altogether, these data suggest that the highly active RUNX2 in KFs could be 
involved in excessive ECM production in keloid tissue. 
Hyperresponsiveness of KFs to dermal tissue-equivalent matrix stiffness causes 
increased expression of RUNX2 and COL11A1 
 It is known that primary cells cultured on TCP dish with a physical stiffness 
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>109 (G) Pa, are spontaneously activated towards myofibroblast differentiation 
(Achterberg et al., 2014; Chen et al., 2014). We postulate that the increased RUNX2 
expression in NFs is associated with the extreme change in matrix stiffness, from 
soft dermal tissue to stiff TCP dish, during primary culture. The effects of matrix 
stiffness on the expression of RUNX2 were investigated by culturing the primary 
dermal fibroblasts on stiff TCP dish (>G Pa), 2 kPa polyacrylamide (PA) gel 
(normal dermis-equivalent stiffness) and 20 kPa PA gel (keloid-equivalent stiffness). 
As shown in Figure 3a and b, the expression of nuclear RUNX2 was increased with 
increasing matrix stiffness in both NFs and KFs. However, KFs expressed higher 
nuclear RUNX2 than NFs did on whichever condition. The expression of FN in KFs 
was prominently elevated with increasing matrix stiffness (Figure 3c). Nevertheless, 
the expression of FN in NFs was only slightly enhanced, despite culturing on the 
TCP dish. We further performed explant culture of fibroblasts on type I 
collagen-coated PA gels of 2 and 20 kPa to diminish the stiff matrix-induced 
RUNX2 activation during primary culture. The mRNA level of RUNX2 and several 
ECM genes were evaluated on Day 3. As shown in Figure 3d and 3e, NFs derived 
from explant culture on 2 and 20 kPa PA gels were devoid of RUNX2 and 
COL11A1. The mRNA levels of FN and COL3A1 of NFs were low on the 2 kPa PA 
gel and increased slightly on the 20 kPa PA gel. KFs derived from explants cultured 
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on 2 kPa PA gels expressed a higher RUNX2, COL11A1, FN, and COL3A1 mRNA 
level than NFs did, which were intensified on 20 kPa PA gels. Collectively, these 
data show that physiologically-equivalent mechanical culture conditions suppress 
the expression of fibrosis-associated RUNX2 and COL11A1 of NFs in comparison 
with conventional stiff TCP. Moreover, it seems that KFs show hyperresponsiveness 
to dermal tissue-equivalent matrix stiffness, which causes increased expression of 
RUNX2 and COL11A1.  
Decreased CAV1 is associated with cell softening and the upregulation of 
fibrogenesis-associated RUNX2 and migratory ability in KFs 
 Although keloids are categorized as a benign fibroproliferative lesions 
selectively occurring in the dermis, their aggressive and recurrent behavior 
resembles that of malignant tumors. Our previous study demonstrated that decreased 
CAV1 contributes to changes in the cell mechanics of cancer cells (Lin et al., 2015). 
The cDNA microarray data revealed that CAV1 level was downregulated in keloid 
tissues (-1.548) compared with adjacent normal tissue. Thus, it is important to 
understand whether CAV1 is also involved in the pathogenesis of keloids, 
particularly from a mechanobiological perspective. Immunofluorescence showed 
that CAV1 was expressed in the cytoplasm and cell membrane of dermal fibroblasts 
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of normal skin, normal scar, and a perilesional normal skin of keloid tissue 
(Supplementary Figure S4). In contrast, CAV1 expression was markedly decreased 
in keloid lesions (Supplementary Figure S4) and KFs (Figure 4a). The potential 
association of CAV1 with cell mechanics of human dermal fibroblasts was studied 
using siRNA to knockdown CAV1 in NFs (Figure 4a and b). CAV1 knockdown 
caused softening of NFs (Figure 4c). When cultured on matrices of varying stiffness, 
siNC (non-targeting control siRNA)-treated NFs altered their stiffness, but 
siCAV1-treated NFs and KFs did not (Figure 4d). The results indicated the loss of 
stiffness sensing ability in siCAV1-treated NFs and KFs. Furthermore, CAV1 
knockdown increased the expression and nuclear translocation of RUNX2 (Figure 
4a, b, e, and f), and increased FN expression (Figure 4a and b) in NFs. Knockdown 
of CAV1 did not change the expression pattern of nuclear RUNX2 in NFs or KFs 
grown on matrices of 20 kPa and 2 kPa (Figure 4g). However, siCAV1-treated NFs 
showed higher percentage of cells with nuclear RUNX2 when cultured on 2 kPa PA 
gel, as compared with siNC-treated NFs. These data suggest that a decrease in CAV1 
might contribute to keloid pathogenesis via elevating fibrogenic RUNX2 expression. 
Immunostaining results showed that dermal fibroblasts in normal and peripheral 
normal skin near the keloid lesion, expressed high CAV1 and extremely low 
RUNX2, while dermal fibroblasts in keloid lesions express low CAV1 and high 
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RUNX2 (Figure 4h). Pearson’s correlation analysis revealed that CAV1 was 
negatively correlated with RUNX2 in keloid lesions (Figure 4i). 
 One characteristic of keloids is their ability to continually migrate beyond the 
original border of a wound (Witt et al., 2008). In vitro studies revealed that KFs 
migrated faster and displayed a higher total force and force per post than NFs (Harn 
et al., 2015; Witt et al., 2008). Also, Cav1-depleted NIH3T3 fibroblasts displayed 
increased cell migration (Lin et al., 2015). Here, we found that CAV1 knockdown by 
siRNA increased migratory ability (Figure 5a and Supplementary Figure S5) and 
force per post of NFs (siCav/NFs vs. siNC/NFs: 4.18 ± 0.14 nN vs. 3.53 ± 0.08 nN) 
(Figure 5b and c). Further, both MLC2 protein and MLC2 phosphorylation, the 
relevant mediators of transcellular contractility (Iwabu et al., 2004), were markedly 
increased in KFs and in CAV1-depleted NFs (Figure 5d and e). Collectively, these 
data show that KFs are softer and migrate faster than NFs, which may correlate with 
the decrease in CAV1.  
TSA, an HDA  inhibitor, inhibited histone deacetylase, increased CAV1 and 
decreased RUNX2 in KFs 
 Considering that CAV1 downregulation only occurs in actual keloid lesions, 
CAV1 might be under epigenetic regulation. HDAC2, an epigenetically-regulated 
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enzyme, is strikingly upregulated in keloid scars (Fitzgerald O'Connor et al., 2012). 
Moreover, inhibition of HDAC by TSA diminished collagen synthesis in KFs (Diao 
et al., 2011). Here, treatment of KFs with TSA increased acetylation of K9 of 
histone H3 (histone H3AK9) and CAV1 expression (Figure 6a-d). Consequently, 
TSA-treated KFs showed the phenotype toward normal, including decreased 
expression of RUNX2 and FN (Figure 6e and f), migratory ability (Figure 6g), and 
increased cell stiffness (Figure 6h). Finally, TSA-treated KFs showed decreased 
percentage of cells with nuclear RUNX2 when cultured on 2 kPa PA gel (Figure 6i). 
Collectively, these data suggest the important role of epigenetics-modulated CAV1 
in the pathogenesis of keloid scars.  
DISCUSSION 
 In this study, we showed that CAV1 downregulation played a critical role in the 
pathogenesis of keloids. The finding is consistent with those from Zhang et al. (2011) 
who showed that CAV1, antagonizing profibrotic processes by decreasing TGF-β 
receptor type I and Smad2/3 phosphorylation, was markedly decreased in 
keloid-derived fibroblasts. Given CAV1 levels in keloid lesions were substantially 
lower in comparison with perilesional skin of the keloid (Supplementary Figure S4) 
and HDACs inhibitor TSA increased CAV1 in KFs (Figure 6a), epigenetic 
modifications involvement in the decrease of CAV1 are suggested. In vivo studies of 
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mouse and human skin wounds revealed that HDAC2 is markedly increased in both 
normal and keloid scar tissues (Fitzgerald O'Connor et al., 2012). Whether the 
heightened HDAC2 is relevant to epigenetically downregulated CAV1 in keloid 
lesions remains unknown. Given the normal scar tissues normally expressed CAV1 
(Supplementary Figure S4), it is possible that other epigenetic modifying enzymes 
dominate the CAV1 downregulation or other factors are required to potentiate the 
action of HDAC2 in keloid lesions. 
 CAV1 has been implicated in pathological conditions of abnormal collagen 
expression in the skin. When Cav1 was knockout, mice exhibited scleroderma-like 
pathological skin features, characterized by upregulated expression of dermal 
collagens (Castello-Cros et al., 2011), or had greater bone size and stiffness, along 
with an increase in alkaline phosphatase protein and expression of osterix and Runx2 
(Rubin et al., 2007). In human dermal fibroblasts, CAV1 inhibition by 
methyl-β-cyclodextrin led to upregulation of collagen expression (Lee et al., 2015). In 
this study, the Ingenuity Pathway Analysis (IPA) data show that “the role of 
osteoblasts, osteoclast, and chondrocytes in rheumatoid arthritis” is the most 
important signaling pathway in keloids (Supplementary Figure S2), which are 
consistent with those from Naitoh et al. (2005) who showed that gene expression in 
human keloids is altered from dermal to chondrocytic and osteogenic lineage. 
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Noteworthy, RUNX2, the osteogenesis-specific transcription factor, is ectopically 
expressed in KFs in vitro and in vivo (Figure 4) (Naitoh, 2005). In osteoblasts, Runx2 
was found to be a target of mechanical signals mediated by Ras/ERK1/2 MAPK 
signaling (Kanno et al., 2007; Ziros et al., 2002). Runx2 was also shown to be an 
inducer of aortic fibrosis and stiffness (Raaz et al., 2015). Silencing CAV1 with 
siRNA in NFs, increased RUNX2 expression (Figure 4a), whereas enhancing CAV1 
with TSA treatment in KFs suppressed RUNX2 expression (Figure 6a and b), 
suggesting that the repressive role of CAV1 in RUNX2 expression. Cav1, the main 
component of caveolae, have been shown to serve as scaffolds for a variety of 
signaling molecules and negatively regulate signal penetrance (Boscher and Nabi, 
2012). Accordingly, silencing CAV1 might relief the signals that lead to the 
expression RUNX2 in keloids. However, the expression of RUNX2 was also reported 
to be modulated by HDAC inhibitors in different cell types. Saito et al. (2013) showed 
cyclic tensile strain-induced expression of RUNX2 was suppressed by TSA in human 
chondrocytes. Conversely, Cho et al. (2005) showed that valproic acid treatment 
increased RUNX2 expression and osteogenic differentiation of human bone marrow 
stromal cells and human adipose tissue-derived stromal cells. This discrepancy may 
be explained by cell type differences, which initiate various signaling pathway. 
Although we suggest that TSA upregulated-CAV1 play a critical role in the 
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suppression of RUNX2, we cannot rule out the possibility that TSA treatment 
suppresses RUNX2 expression bypassing CAV1 restoration. 
 Expression of COL11A1 is very low or absent in normal skin. In several types of 
cancer, high expression of COL11A1 occurred in the invasive carcinoma and 
activated stromal cells of the desmoplastic reaction, and this expression is correlated 
with carcinoma aggressiveness and progression, and lymph node metastasis (Raglow 
and Thomas, 2015; Vazquez-Villa et al., 2015). Here, the cDNA microarray data 
indicates that COL11A1 is the most highly upregulated collagen gene in KFs related 
to NFs, which coincided with previous findings (Chen et al., 2003, Naitoh et al., 2005, 
Seifert et al., 2008). RUNX2 knockdown by siRNA significantly decreased COL11A1 
(Supplementary Figure S3), suggesting that RUNX2 is vital for the expression of 
COL11A1 in keloid fibroblasts. Although the function of COL11A1 in keloid remain 
unknown, it is plausible that COL11A1 might confer keloid fibroblasts the invasive 
ability to spread outside the original injury site. However, more in-depth studies are 
needed to determine the mechanism through which COL11A1 influences keloid 
fibroblasts behavior. In summary, RUNX2/COL11A1 expression might be a 
remarkable biomarker of keloid fibroblasts and an ideal target for future therapies in 
keloid. 
 Matrices of physiologic stiffness potently inhibit normal cell proliferation (Klein 
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et al., 2009; Lin et al., 2015) and TGF-β-induced fibrosis (Chen et al., 2014; Leight et 
al., 2012), thus, regulation of tissue stiffness level is fundamental for the 
physiological function of organs. Discordance of cell and matrix stiffness has been 
hypothesized to contribute to the pathogenesis of cancer and scarring (Janmey and 
Miller, 2011). Here, we found that KFs shared similar mechanical phenotypes with 
cancer cells, including cell softening and loss of stiffness sensing ability due to 
decreased CAV1 (Lin et al., 2015). Cav1 is linked to the formation of actin cap, which 
dominates cell stiffness and mechanosensing in NIH3T3 fibroblasts (Lin et al., 2015). 
However, immunostaining results showed that microtubule polymerization, but not 
actin cap organization, was weakened in KFs compared to NFs (data not shown). 
Microtubules function as rigid struts and contribute to cytoskeletal stiffness as well as 
cellular contractions. Kawabe et al. (2006) demonstrated that downregulation of 
caveolins attenuated microtubule polymerization, which indirectly regulates cellular 
signaling. Microtubule disruption has been reported to increase the isometric cell 
force, an effect attributed to either change in intracellular Ca2+ (Paul et al., 2000), 
which regulates actomyosin contractility, or increases in MLC phosphorylation, 
resulting from the release of tubulin monomers (Birukova et al., 2004; Kolodney and 
Elson, 1995). Altogether, it seems reasonable to propose that decreased CAV1 may 
inhibit microtubule polymerization, which decreases cell stiffness (Figure 4c) but 
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increases contractile forces, resulting from MLC2 activation (Figure 5b-e) in KFs. 
Cells sense stiffness through mechanosensing of strains on their cytoskeletons by 
outside-in signaling mechanisms (Discher et al., 2005). These forces, exerted on the 
cells, trigger further changes in morphology and phenotype (Engler et al., 2006; 
Goldmann, 2014). Although CAV1 is linked to the stiffness sensing ability of KFs, the 
underlying mechanism remains unclear. Previous studies showed that β1 
integrin-mediated mechanotransduction is mediated by caveolae domains (Radel et al., 
2007; Wei et al., 2008). CAV1 has been shown to inhibit metastatic potential in 
melanomas through suppression of the integrin/Src/FAK signaling pathway (Trimmer 
et al., 2010). Suarez et al. (2013) found that three specific tension-related genes and 
proteins (Hsp27, α2β1 integrin, and PAI-2), are overexpressed in keloids and regulate 
ECM production. Altogether, it is plausible that CAV1 interacts with the integrin/FAK 
network to regulate the mechanotransduction of the skin. There are some animal 
models developed to mimic hypertrophic scar (Ibrahim et al., 2014; Wong et al., 2011) 
or keloid (Lee et al., 2016). It would be interesting to further test our hypothesis 
through these in vivo models. 
 In conclusion, we highlight a novel role of CAV1 in the progression of keloids 
(see also Schematic model in Supplementary Figure S5). Epigenetically decreased 
CAV1 increases fibrogenesis-associated RUNX2 and alters cell mechanics, 
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including cell softening, loss of stiffness sensing ability, and increase in contractile 
forces. Consequently, keloid-derived fibroblasts exhibit hyperresponsiveness to both 
normal dermis-equivalent stiffness (2 kPa) and pathological keloid-equivalent 
stiffness (20 kPa) or have established an activated state of fibrogenesis-associated 
RUNX2 that is independent of mechanical cues. These results could explain why 
KFs produce excessive ECM and prominently migrate into the surrounding normal 
dermal tissue, thus generating the main clinicopathologic hallmarks of keloids. 
MATERIALS AND METHODS 
Human samples  
    The study was approved by the Institutional Review Board at the National Cheng 
Kung University Hospital (NCKUH-10105017/BR-100-102). Participants gave their 
written informed consent, and as detailed in the Supplementary Materials and 
Methods.  
Primary culture of fibroblasts 
 Fibroblasts were isolated from dermal tissues, according to Zhang et al. (2009) 
and as detailed in the Supplementary Materials and Methods.  
Measurements of cell/tissue mechanical properties by AFM 
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 For measurements of cell/tissue stiffness, a JPK NanoWizard II AFM with 
BioCell (JPK Instruments, Berlin, Germany) was equipped and manipulated as 
previously described (Chiou et al., 2013; Harn et al., 2015; Lin et al., 2015) and as 
detailed in the Supplementary Materials and Methods.  
Preparation and fabrication of Polyacrylamide (PA) gels 
 PA gels with uniform stiffness were prepared as previously described (Chen et 
al., 2014; Lin et al., 2015) and as detailed in the Supplementary Material and Methods. 
The Young’s moduli of the PA gels used, were as follows: 2 and 20 kPa PA gels 
represented the elastic modulus of normal and keloid dermis, respectively. PA gels 
from each polymerization batch were checked to verify consistent matrix mechanical 
properties by AFM. 
cDNA microarrays analysis and IPA 
 The microarray study was approved by the ethical committee at Nippon 
Medical School, Tokyo, Japan (No.22-11-143) and detailed in the Supplementary 
Materials and Methods.  
Western blot analyses 
 Cell lysates were harvested in modified RIPA buffer. After sonication, lysates 
were resolved on SDS-PAGE and analyzed by Western blot as detailed in the 
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Supplementary Material and Methods.  
RT-PCR 
    Total RNA was extracted from cells using TRIzol reagent (Invitrogen-Molecular 
Probes, Carlsbad, CA) according to the manufacturer’s instructions, and as detailed in 
the Supplementary Materials and Methods. 
Immunofluorescence staining and confocal microscopy 
 Immunofluorescence staining was performed as previously described (Chen et 
al., 2015), and as detailed in the Supplementary Materials and Methods.  
Immunohistochemistry (IHC) 
    IHC was performed, as previously described (Lee et al., 2010), and as detailed in 
the Supplementary Materials and Methods. 
Cell transfection with siRNA 
 The expressions of RUNX2 and CAV1 were knocked down using 
commercially available RUNX2 and CAV1 siRNA kits purchased from Dharmacom 
(Upstate, Lake Placid, NY). Fibroblasts at a density of 60% confluence were 
serum-deprived for 24 hours and then transfected with human RUNX2- and 
caveolin-1-specifc siRNA or non-targeting control-siRNA using the Lipofectamine 
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2000 reagent (Invitrogen), according to the manufacturer’s protocol. 
Wound migration assay 
    In vitro wound assays were performed using IBIDI culture inserts according to 
the manufacturer’s instructions, and as detailed in the Supplementary Materials and 
Methods.  
Fabrication of micropost arrays and quantification of traction force 
 PDMS micropost arrays were fabricated using standard microfabrication 
techniques as previously described (Fu et al., 2010; Lin et al., 2015; Yang et al., 
2011b) and detailed in the Supplementary Materials and Methods.  
Statistical analysis  
    Most data are shown as the mean ± SEM of independent experiments. Some data 
were normalized as described in the figure legends and expressed as mean relative 
value ± SEM. Analyses of the results used ANOVA and Student’s t-tests by GraphPad 
Prism 3.0 (GraphPad Software, San Diego, CA). Each experiment was repeated at 
least three times to ensure the validity of the data. Values of p<0.05 were considered 
significant.  
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Figure legends 
Figure 1. Keloid tissues are stiffer than normal tissue, whereas keloid 
fibroblasts (KFs) are softer than normal fibroblasts (NFs). (a) Western blot 
results of skin tissue from control subjects (N=6) and keloid patients (N=6). The 
protein levels of fibronectin (FN), collagen (COL)1A1, COL3A1, COL11A1, and 
GAPDH (internal control) were analyzed. (b) Quantification results of FN, COL1A1, 
COL3A1, and COL11A1 from (a). (c) Atomic force microscopy indentation results 
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of skin tissue dissected from control subjects (N=6) and keloid patients (N=6). (d) 
Western blot results of NFs and KFs derived from control subjects (N=6) and keloid 
patients (N=6), respectively. The protein levels of FN, COL1A1, COL3A1, 
COL11A1 and GAPDH were analyzed. (e) Quantification results of FN, COL1A1, 
COL3A1, and COL11A1 from (d). (f) Stiffness distribution histograms of NFs (N=8) 
and KFs (N=8). (g) Atomic force microscopy indentation results of NFs (N=8) and 
KFs (N=8). *p<0.05, **p<0.01, ***p<0.001. 
Figure 2. RUNX2 is highly upregulated in keloid tissues/fibroblasts. (a) 
Ingenuity pathway analysis results showing the network of RUNX2 and their close 
interactions with several extracellular matrix proteins and matrix metalloproteinases 
(MMPs), which were related to wound healing and scar formation. (b) 
Immunohistochemical staining results for RUNX2 expression in normal skin tissue, 
normal scar tissue, hypertrophic scar, and keloid tissue (N=4 in each). Bar=100 µm. 
(c) Percentage of fibroblasts with nuclear RUNX2 in tissues from (b). (d) 
Representative immunoblots of skin tissue from control subjects and keloid patients. 
The protein levels of p-RUNX2, RUNX2, and GAPDH were analyzed. (e) 
Quantification results of p-RUNX2 and RUNX2 from skin tissue of control subjects 
(N=6) and keloid patients (N=6). (f) Representative immunoblots of NFs and KFs. 
The protein levels of p-RUNX2, RUNX2, and GAPDH were analyzed. (g) 
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Quantification results of p-RUNX2 and RUNX2 from NFs (N=6) and KFs (N=6). 
*p<0.05, **p<0.01, ***p<0.001. 
Figure 3. Keloid dermal fibroblasts show hyperresponsiveness to dermal 
tissue-equivalent matrix stiffness, which causes increased expression of RUNX2 
and COL11A1. (a) Immunofluorescence study of NFs and KFs cultured on matrices 
of varying stiffness for 24 hours. Cells were stained for RUNX2 (green), the nucleus 
(blue), and F-actin (red). Bar=20 µm. (b) Percentage of cells with nuclear RUNX2 
in NFs (N=5) and KFs (N=5) from (a). (c) Western blot results of NFs (N=4) and 
KFs (N=4) cultured on matrices of varying stiffness for 24 hours. (d) Representative 
RT-PCR results of NFs (N=3) and KFs (N=3) derived from explants on matrices of 
varying stiffness at Day 3. The mRNA expressions of RUNX2, COL11A1, 
fibronectin (FN), and COL3A1 were analyzed. (e) Quantification results of RUNX2, 
COL11A1, FN, and COL3A1 mRNA from (d). GAPDH-normalized data were 
compared with those of NFs cultured on 2 kPa PA gel. *p<0.05, ***p<0.001. 
Figure 4. Suppression of CAV1 in NFs causes cell softening, loss of stiffness 
sensing ability, and increased expression of RUNX2 and FN. (a) Western blot 
results of NFs transfected with non-targeting control siRNA (siNC) or siCAV1 for 
48 h and KFs. (b) Quantification results of CAV1, RUNX2, and FN from (a). 
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GAPDH-normalized data were compared with those of NFs (N=3) transfected with 
siNC. CAV1 knockdown in NFs causes (c) cell softening, (d) inability to change cell 
stiffness on matrices of varying stiffness. (e) Confocal immunofluorescence images 
obtained with anti-RUNX2 (green) in NFs and KFs cultured on dishes and treated 
with siNC or siCAV1 for 24 hours. Bar=50 µm. (f) Percentage of cells with nuclear 
RUNX2 in dermal fibroblasts from (e). (g) Percentage of cells with nuclear RUNX2 
in siNC- or siCAV1-transfected NFs and KFs grown on PA gels of 20 kPa and 2 kPa 
for 24 h. (h) Confocal immunofluorescence images obtained with anti-CAV1 (red), 
anti-RUNX2 (green), and nucleus (blue) in skin tissues from control subjects (N=2) 
and keloid patients (N=3). Bar=50 µm. (i) Pearson’s correlation comparing CAV1 
and RUNX2 intensity in skin tissues from (h). *p<0.05, **p<0.01, ***p<0.001. 
Figure 5. CAV1 knockdown promotes migratory ability of NFs. NFs (N=3) and 
KFs (N=3) were transfected with siNC or siCAV1 for 24 h. After reaching a 
confluent monolayer, wound healing experiments were performed. (a) 
Quantification results of wound scratch (0 h) and recovery (8 h and 24 h) from 
Supplementary Figure S5. Wound recovery (%)=[(wound area at 0 hours–wound 
area at 24 hours)/wound area at 0 hours]*100%. (b) The representative force maps 
of fibroblasts under indicated conditions plated on PDMS micropost arrays. The 
color scale indicates the magnitude of traction force (nN). (c) Quantification results 
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of total force and force per post generated in cells from (b). (d) Western blot results 
of NFs or KFs transfected with siNC and siCAV1 for 48 hours. The protein levels of 
CAV1, pMLC2, MLC2, and GAPDH were analyzed. (e) Quantification results of 
CAV1, pMLC2, and MLC2 from (d). *p<0.05, **p<0.01. 
Figure 6. Epigenetic control of CAV1 impacts on cell mechanics and RUNX2 
expression in KFs. (a) Confocal immunofluorescence images of KFs plated onto 
culture dishes and treated with various doses of TSA for 24 hours. Bar=20 µm. (b) 
Western blot results of KFs (N=3) under indicated conditions. The protein levels of 
CAV1, RUNX2, FN, histone H3 acetyl K9 (histone H3AK9), and GAPDH were 
analyzed. Quantification results of (c) histone H3AK9, (d) CAV1, (e) RUNX2, and 
(f) FN from (b). GAPDH-normalized data were compared with those of KFs treated 
with DMSO (TSA 0 µM). Treatment of KFs with 200 nM TSA (g) hindered wound 
recovery, (h) increased cell stiffness, and (i) decreased the percentage of cells with 
nuclear RUNX2 on 2 kPa. *p<0.05, **p<0.01, ***p<0.001. 
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